At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 92 enrolled
Drug / intervention
Zenoctil +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized, Placebo-controlled, Bicentric Study to Evaluate the Safety and Efficacy of Zenoctil in Reducing Body Weight of Overweight Subjects
In Brief
A Phase 3 clinical trial evaluating Zenoctil and Placebo for Overweight. Completed, enrolled 92 participants across 1 site.
Detailed Summary
The intention of the study is to evaluate the safety and potential body weight and body fat loss effects of a 12-week treatment with Zenoctil in a randomized, double-blind, placebo-controlled, parallel study conducted in Caucasian subjects. This study will also include a diet plan for each subject, calculated based on gender, age, and energy requirements; and adjusted to be slightly hypocaloric.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedAug 2011
Primary CompletionDec 2011
TodayJul 2026
First PostedAug 26, 2011
Enrollment StartJul 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.8 years ago
Interventions
Zenoctildietary
3 tablets 2 times daily
Placeboother
3 tablets 2 times daily